R. A. Rudick

2.4k total citations
19 papers, 1.3k citations indexed

About

R. A. Rudick is a scholar working on Pathology and Forensic Medicine, Neurology and Rheumatology. According to data from OpenAlex, R. A. Rudick has authored 19 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Pathology and Forensic Medicine, 4 papers in Neurology and 4 papers in Rheumatology. Recurrent topics in R. A. Rudick's work include Multiple Sclerosis Research Studies (13 papers), Rheumatoid Arthritis Research and Therapies (3 papers) and Viral Infections and Immunology Research (2 papers). R. A. Rudick is often cited by papers focused on Multiple Sclerosis Research Studies (13 papers), Rheumatoid Arthritis Research and Therapies (3 papers) and Viral Infections and Immunology Research (2 papers). R. A. Rudick collaborates with scholars based in United States, Canada and Poland. R. A. Rudick's co-authors include Gary Cutter, Stephen C. Reingold, Donald E. Goodkin, B. Weinstock‐Guttman, Jill S. Fischer, James E. Aikens, Marie Namey, R. M. Ransohoff, Bianca Weinstock‐Guttman and Monika Baier and has published in prestigious journals such as Neurology, Journal of the Neurological Sciences and Journal of Neuroimmunology.

In The Last Decade

R. A. Rudick

19 papers receiving 1.2k citations

Peers

R. A. Rudick

PFM

NEURO

RHEUM

ONCOL

IMMUN

B. Weinstock‐Guttman United States

Pierrette Seeldrayers Belgium

R. Phillip Kinkel United States

Peter Brex United Kingdom

M. Rodegher Italy

Giancarlo Comi Italy

Bettina Stubinski Switzerland

Carolyn Bevan United States

HP Hartung Germany

Leszek Stawiarz Sweden

B. Weinstock‐Guttman United States

R. A. Rudick

1.3k ×1.3

PFM

423 ×1.3

NEURO

381 ×1.2

RHEUM

340 ×1.1

ONCOL

327 ×1.3

IMMUN

Citations per year, relative to R. A. Rudick R. A. Rudick (= 1×) peers B. Weinstock‐Guttman

Countries citing papers authored by R. A. Rudick

Since Specialization

Citations

This map shows the geographic impact of R. A. Rudick's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by R. A. Rudick with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites R. A. Rudick more than expected).

Fields of papers citing papers by R. A. Rudick

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by R. A. Rudick. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by R. A. Rudick. The network helps show where R. A. Rudick may publish in the future.

Co-authorship network of co-authors of R. A. Rudick

This figure shows the co-authorship network connecting the top 25 collaborators of R. A. Rudick. A scholar is included among the top collaborators of R. A. Rudick based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with R. A. Rudick. R. A. Rudick is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

Rudick, R. A., Robert Hyde, B. Weinstock‐Guttman, et al.. (2009). FP39-WE-02 A 15-year follow-up study to identify early predictors of long-term response to intramuscular interferon beta-1a therapy in patients with relapsing-remitting multiple sclerosis. Journal of the Neurological Sciences. 285. S119–S119. 6 indexed citations

Rudick, R. A., et al.. (2007). The kinetics of brain atrophy during the first year of treatment with natalizumab. UCL Discovery (University College London). 1 indexed citations

Calabresi, Peter A., Gavin Giovannoni, Christian Confavreux, et al.. (2007). The incidence and significance of anti-natalizumab antibodies. Neurology. 69(14). 1391–1403. 236 indexed citations

Rudick, R. A., et al.. (2007). Optimal reference population for the multiple sclerosis functional composite. Multiple Sclerosis Journal. 13(7). 909–914. 22 indexed citations

Baier, Monika, Gary Cutter, R. A. Rudick, et al.. (2005). Low-contrast letter acuity testing captures visual dysfunction in patients with multiple sclerosis. Neurology. 64(6). 992–995. 124 indexed citations

Rudick, R. A., Gary Cutter, & Stephen C. Reingold. (2002). The Multiple Sclerosis Functional Composite: a new clinical outcome measure for multiple sclerosis trials. Multiple Sclerosis Journal. 8(5). 359–365. 178 indexed citations

Pelfrey, Clara M., et al.. (2001). Immunomodulatory effects of interferon beta-1a in multiple sclerosis. Journal of Neuroimmunology. 112(1-2). 153–162. 85 indexed citations

Fisher, Elizabeth, R. A. Rudick, Monika Baier, et al.. (2000). Relationship between brain atrophy and disability: an 8-year follow-up study of multiple sclerosis patients. Multiple Sclerosis Journal. 6(6). 373–377. 19 indexed citations

Rudick, R. A., Nancy A. Simonian, Jehan Alam, et al.. (1998). Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis. Neurology. 50(5). 1266–1272. 262 indexed citations

10.

Aikens, James E., Jill S. Fischer, Marie Namey, & R. A. Rudick. (1997). A Replicated Prospective Investigation of Life Stress, Coping, and Depressive Symptoms in Multiple Sclerosis. Journal of Behavioral Medicine. 20(5). 433–445. 100 indexed citations

11.

Beck, R., et al.. (1996). Cerebrospinal fluid in acute optic neuritis. Neurology. 46(2). 368–372. 53 indexed citations

12.

Goodkin, Donald E., et al.. (1996). Low-dose oral methotrexate in chronic progressive multiple sclerosis. Neurology. 47(5). 1153–1157. 42 indexed citations

13.

Goodkin, Donald E., R. A. Rudick, & Jeffrey S. Ross. (1994). The Use of Brain Magnetic Resonance Imaging in Multiple Sclerosis. Archives of Neurology. 51(5). 505–516. 32 indexed citations

14.

Jacobs, L. D., et al.. (1994). Results of a phase III trial of IM recombinant beta interferon as treatment for MS. Journal of Neuroimmunology. 54(1-2). 170–170. 5 indexed citations

15.

Rudick, R. A., Donald E. Goodkin, & R. M. Ransohoff. (1992). Pharmacotherapy of multiple sclerosis: current status. Cleveland Clinic Journal of Medicine. 59(3). 267–277. 15 indexed citations

16.

Goodkin, Donald E., R. M. Ransohoff, & R. A. Rudick. (1992). Experimental therapies for multiple sclerosis: current status. Cleveland Clinic Journal of Medicine. 59(1). 63–74. 17 indexed citations

17.

Goodkin, Donald E., R. A. Rudick, Tom Greene, et al.. (1992). Low-dose (7.5 mg) oral methotrexate for chronic progressive multiple sclerosis. Design of a randomized, placebo-controlled trial with sample size benefits from a composite outcome variable including preliminary data on toxicity.. PubMed. Doc No 19. [7723 words; 89 paragraphs]–[7723 words; 89 paragraphs]. 7 indexed citations

18.

Goodkin, Donald E., et al.. (1991). Diagnostic Criteria for Multiple Sclerosis Research Involving Multiply Affected Families. Archives of Neurology. 48(8). 805–807. 41 indexed citations

19.

Swick, Alan R., et al.. (1991). Sensitive competitive‐binding elisas for quantifying free kappa and lambda light chains in cerebrospinal fluid. Journal of Clinical Laboratory Analysis. 5(3). 206–211. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact